Open Access

Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review)

  • Authors:
    • Xingwen Han
    • Wenji Wang
    • Jingjing He
    • Lei Jiang
    • Xun Li
  • View Affiliations

  • Published online on: January 8, 2019     https://doi.org/10.3892/ol.2019.9905
  • Pages: 2592-2598
  • Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma (OS) is the most common bone malignancy, and is particularly prevalent in children and adolescents. OS is an aggressive tumor with a tendency to metastasize and invade to para‑carcinoma tissues. The primary treatment for this tumor is a combination of surgery and chemotherapy. However, the prognosis remains poor due to chemoresistance and early metastasis. Osteopontin (OPN), a multifunctional secreted protein, has emerged as an important potential biomarker for diagnosing and treating cancer. The overexpression of OPN has been found in numerous malignant tumors, including breast, lung, gastric and ovarian cancer, as well as melanoma. Recent studies have suggested that OPN may provide an important function in the diagnosis and treatment of OS. The present review summarizes current knowledge and progress in understanding the potential role of OPN as a biomarker in OS.
View Figures
View References

Related Articles

Journal Cover

March-2019
Volume 17 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Han X, Wang W, He J, Jiang L and Li X: Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review). Oncol Lett 17: 2592-2598, 2019
APA
Han, X., Wang, W., He, J., Jiang, L., & Li, X. (2019). Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review). Oncology Letters, 17, 2592-2598. https://doi.org/10.3892/ol.2019.9905
MLA
Han, X., Wang, W., He, J., Jiang, L., Li, X."Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review)". Oncology Letters 17.3 (2019): 2592-2598.
Chicago
Han, X., Wang, W., He, J., Jiang, L., Li, X."Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review)". Oncology Letters 17, no. 3 (2019): 2592-2598. https://doi.org/10.3892/ol.2019.9905